UK Markets closed

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
7.26-0.39 (-5.10%)
As of 04:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close7.65
Bid7.22 x 2200
Ask7.25 x 3200
Day's range7.18 - 7.90
52-week range0.28 - 18.77
Avg. volume32,863,596
Market cap1.439B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    3 Small-Cap COVID Stocks With Huge Upside

    While large-cap stocks are usually safer, small-cap stocks are often way more exciting. If you own the right small cap, you can make a lot of money as your company becomes the large cap of tomorrow. This panel of contributors has three small-cap COVID-19 stock ideas for intrepid investors.

  • Motley Fool

    Better Buy: Ocugen or Novavax?

    There may be a second wave of COVID-19 vaccines coming. With the hopes of widespread approval of each company's SARS-CoV-2 vaccine, Novavax (NASDAQ: NVAX) is already up nearly 90% year to date while Ocugen (NASDAQ: OCGN) is up over 300% in the same time frame. Patrick Bafuma: To begin, let's take a look at Novavax.

  • Motley Fool

    Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen

    Inovio Pharmaceuticals (NASDAQ: INO) and Ocugen (NASDAQ: OCGN) are two small biotechs that hope to win regulatory authorizations for COVID-19 vaccines in the not-too-distant future. In this Motley Fool Live video recorded on Nov. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how these two COVID-19 contenders stack up against each other. Keith Speights: There are two companies that hope to market COVID-19 vaccines: Inovio and Ocugen.